The significance of glucose turnover in the brain in the pathogenetic mechanisms of Alzheimer's disease

Reviews in the Neurosciences

Volumn 7, Issue 1, 1996, Pages 1-19

  Meier Ruge, W ^a   Bertoni Freddari, C ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NONE

Author keywords

AcCoA; Acetylcholine; Alzheimer's disease; ATP; Beta amyloid; Beta amyloid precursor protein; Brain glucose turnover; Etiology; Glycolysis; Pathogenesis

Indexed keywords

ACETYLCHOLINE; AMINO ACID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASPARTIC ACID; CALCIUM; CHOLINE; FREE RADICAL; GLUTAMIC ACID; MITOCHONDRIAL DNA; NEUROTRANSMITTER; PROTEIN KINASE; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN METABOLISM; CALCIUM TRANSPORT; CHROMOSOME 21; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIGH ENERGY PHOSPHATE; HUMAN; OXIDATIVE PHOSPHORYLATION; POINT MUTATION; PRIORITY JOURNAL; REVIEW;

EID: 0029994450     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro.1996.7.1.1     Document Type: Review

References (207)

1. Abe K, George-Hyslop PH, Tanzi RE, Kogure K. Induction of amyloid precursor protein in RNA after heat shock in cultured human lymphoblast cells. Neurosci Lett 1991; 125: 169-171.
2. Abe K, Tanzi RE, Kogure K. Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex. Neurosci Lett 1991; 125: 172-174.
3. Alavi A, Newberg AB, Souder E, Berlin JA. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators. J Nucl Med 1993; 34: 1681-1687.
4. Araki W, Kitaguchi N, Tokushima Y, Ishii K, Aratake H, Shimohama S, Nakamura S, Kumura J. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Comm 1992; 181: 265-271.
5. Azari NP, Rapoport SI, Salerno JA, Grady CL, Gonzalez-Aviles A, Schapiro MB, Horwitz B. Interregional correlations of resting cerebral glucose metabolism in old and young women. Brain Res 1992; 589: 279-290.
6. Barger SW, Smith-Swintosky VL, Rydel RE, Mattson MP. β-Amyloid precursor protein mismetabolism and loss of calcium homeostasis in Alzheimer's disease. Ann NY Acad Sci 1993; 695: 158-164.
7. Baron JC, Marchal G. Viellissement cerebral et cardiovasculaire et metabolisme energetique cerebral. Etudes chez l'homme par la tomographie a positions. Presse Med 1992; 21: 1231-1237.
8. Beal MF. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 1992; 31: 119-130.
9. Beal MF. Energy, oxidative damage, and Alzheimer's disease: clues to the underlying puzzle. Neurobiol Aging 1994; 15 (suppl 2): 171-174.
10. Bennett MC, Diamond DM, Stryker SL, Parks KJ, Parker WD Jr. Cytochrome oxidase inhibition: a novel animal model of Alzheimer's disease. Geriatr Psychiatry 1992; 5: 93-101.
11. Bertoni-Freddari C, Fattoretti P, Casoli T, Meier-Ruge W, Ulrich J. Reactive capacities of the central nervous system in physiological aging and senile dementia of the Alzheimer type. Ann NY Acad Sci 1991; 621: 98-103.
12. Bertoni-Freddari C, Fattoretti P, Casoli T, Pieroni M, Meier-Ruge W, Ulrich J. Neurobiology of the aging brain: morphological alteration at synaptic regions. Arch Gerontol Geriatr 1991; 12: 253-259.
13. Bertoni-Freddari C, Fattoretti P, Casoli T, Spagna C, Meier-Ruge W, Ulrich J. Morphological plasticity of synaptic mitochondria during aging. Brain Res 1993; 628: 193-200.
14. Bertoni-Freddari C, Fattoretti P, Pieroni M, Meier-Ruge W, Ulrich J. Enlargement of synaptic size as a compensative reaction in aging and dementia. Path Res Pract 1992; 188: 612-615.
15. Beyreuther K, Bush AJ, Dyrks TH, Hilbich C, König G, Mönning U, Multhaup G, Prior R, Rumble B, Schubert W, Small DH, Weidemann A, Masters CL. Mechanisms of amyloid deposition in Alzheimer's disease. Ann NY Acad Sci 1991; 640: 129-139.
16. Blass JP. Pathophysiology of Alzheimer syndrome. Neurology 1993; 43 (suppl 4): 25-38.
17. Blass JP, Baker AC, Ko LW, Black RS. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 1990; 47: 864-869.
18. Blass JP, Gibson GE. The role of oxidative abnormalities in the pathophysiology of Alzheimer's disease. Rev Neurol (Paris) 1991; 147: 513-525.
19. Bowen DM. Treatment of Alzheimer's disease. Molecular pathology versus neurotransmitter-based therapy. Br J Psychiatry 1990; 157: 327-330.
20. Bowen DM, Spillane JA, Curzon G, Meier-Ruge W, White P, Goodhardt MJ, Iwangoff P, Davison AN. Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet 1974; i: 11-14.
21. Bowling AC, Mutisya EM, Walker LC, Price DL, Cork LC, Beal MF. Age-dependent impairment of mitochondrial function in primate brain. J Neurochem 1993; 60: 1964-1967.
22. Buchsbaum MS, Kesslak JP, Lynch G, Chui H, Wu J, Sicotte N, Hazlett E, Teng E, Cotman CW. Temporal and hippocampal metabolic rate during an olfactory memory task assessed by positron emission tomography in patients with dementia of the Alzheimer type and controls. Preliminary studies. Arch Gen Psychiatry 1991; 48: 840-847.
23. Budinger ThF. Future research in Alzheimer's disease using imaging techniques. Neurobiol Aging 1994; 15 (suppl 2): 41-48.
24. Bugiani O, Giaccone G, Verga L, Pollo B, Ghetti B, Frangione B, Tagliavini F. Alzheimer patients and Down patients: abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neurosci Lett 1990; 119: 56-59.
25. Bush AI, Pettingell WH, Multhaup G, Paradis M de, Vonsattel JP, Gusella JF, Beyreuther K, Masters CL, Tanzi RE. Rapid induction of Alzheimer A-beta amyloid formation by zinc. Science 1994; 265: 1464-1467.
26. Caporaso GL, Gandy SE, Buxbaum JD, Ramabhadran TV, Greengard P. Protein phosphorylation regulates Alzheimer beta/A-4 amyloid precursor protein. Proc Natl Acad Sci USA 1992; 89: 3055-3059.
27. Chapman J, Alory G, Weiss Z, Faigon M, Feldon J, Michaelson DM. Anti-neuronal antibodies similar to those found in Alzheimer's disease induce memory dysfunction in rats. Neuroscience 1991; 40: 297-305.
28. Chartier-Harlin M-C, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, Mullan M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991; 353: 844-846.
29. Cole GM, Bell LL, Truong QB, Saitoh T. An endosomal-lysosomal pathway for degradation of amyloid precursor protein. Ann NY Acad Sci 1992; 674: 103-117.
30. Cole GM, Huynh TV, Saitoh T. Evidence for lysosomal processing of amyloid beta-protein precursor in cultured cells. Neurochem Res 1989; 14: 933-939.
31. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, Small GW, Roses AD, Haines J, Pericak-Vance MA. Apolipoprotein E type 2 allele decreases the risk of late-onset Alzheimer disease. Nature Genet 1994; 7: 180-184.
32. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Small GW, Roses AD, Haines J, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
33. Craft S, Zallen G, Baker LD. Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsych 1992; 14: 253-267.
34. Davies P, Maloney AFJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; ii: 1403.
35. Delaère P, Duyckaerts C, Brion JP, Piette F, Hauw JJ. Relationship between tau, paired helical filaments, amyloid and the intellectual deterioration in the neocortex in normal aging and in senile dementia. In: Boller F, Katzman R, Rascol A, Signoret JL, Christen Y, eds. Biological Workers of Alzheimer's Disease. Berlin, Heidelberg, New York: Springer, 1989; 73-82.
36. Dolezal V, Tucek S. Effect of choline and glucose on atropine-induced alterations of acetylcholine synthesis and content in brain of rats. Brain Res 1982; 240: 285-293.
37. Duara P, Barker WW, Chang J, Yoshii F, Loewenstein DA, Pascal S. Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease. J Cereb Blood Flow Metab 1992; 12: 927-934.
38. Emerit I, Chance B. Free Radicals and Aging. 2nd ed. Basel: Birkhäuser, 1994.
39. Erecinska M, Silver IA. ATP and brain functions. J Cerebr Blood Flow Metab 1989; 9: 2-19.
40. Estus S, Golde TE, Kunishita T, Blades D, Lowery D, Eisen M, Usiak M, Qu XM, Tabira T, Greenberg BD, Younkin SG. Potentially amyloidogenic, carboxyl-terminal derivation of the amyloid protein precursor. Science 1992; 255: 726-728.
41. Estus S, Golde TE, Younkin SG. Normal processing of the Alzheimer's disease amyloid β protein precursor generates potentially amyloidogenic carboxyl-terminal derivatives. Ann NY Acad Sci 1992; 674: 138-148.
42. Evans RJ, Derkach V, Surprenant A. ATP mediates fast synaptic transmission in mammalian neurons. Nature 1992; 357: 503-505.
43. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. TINS 1991; 14: 2991.
44. Fleming JE, Miquel J, Cottrell SF, Yengoyan LS, Economos AC. Is cell aging caused by respiration-dependent injury to the mitochondrial genome? Gerontology 1982; 28: 44-53.
45. Friedland RP, Budinger TF, Koss E, Ober BA. Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 1985; 53: 235-230.
46. Friedlich AL, Butcher LL. Involvement of free oxygen radicals in β-amyloidosis: an hypothesis. Aging 1994; 15: 443-455.
47. Fukuyama H, Harda K, Yamauchi H, Miyoshi T, Yamaguchi S, Kimura J, Kameyama M, Senda M, Yonekura Y, Konishi J. Coronal reconstruction images of glucose metabolism in Alzheimer's disease. J Neurol Sci 1991; 106: 128-134.
48. Gabuzda DH, Bugiciglio J, Chen LB, Matsudaira P, Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 1994; 269: 13623-13628.
49. Gedye A, Beattic BL, Tuokko H, Horton A, Korsarek E. Severe head injury hastens age of onset of Alzheimer's disease. J Am Geriatr Soc 1989; 37: 970-973.
50. George-Hyslop PH St, Tanzi RE, Haines JL, Polinsky RJ, Farrer L, Myers RH, Gusella JF. Molecular genetics of familial Alzheimer's disease. Eur Neurol 1989;29 (suppl 3): 25-27.
51. George-Hyslop PH St, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, Growdon J, Bruni A, Foncin JF, Salmon D, Frommelt P, Amaducci L, Sorbi S, Piacentini S, Stewart GD, Hobbs WJ, Conneally M, Gusella JF. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 1987; 235: 885-890.
52. George-Hyslop PH St, Tanzi RE, Polinsky RJ, Neve RL, Pollen D, Drachman D, Growdon J, Cupples LA, Nee L, Myers RH, O'Sullivan D, Watkins PC, Amos JA, Deutsch CK, Bodfish JW, Kinsbourne M, Feldman RG, Bruni A, Amaducci L, Foncin JF, Gusella JF. Absence of duplication of chromosome 21 genes in familial and sporadic Alzheimer's disease. Science 1987; 238: 664-666.
53. George-Hyslop PH St, members of the FAD collaborative study group. Genetic linkage studies suggest that Alzheimer's disease is not a single homogenous disorder. Nature 1990; 347: 194-197.
54. Gething MJ, Sambrook J. Protein folding in the cell. Nature 1992; 355: 33-45.
55. Gibbs EL, Lennox WG, Nims LF, Gibbs FA. Arterial and cerebral venous blood. Arterial-venous differences in man. J Biol Chem 1942; 144: 325-332.
56. Gibson BE, Jope R, Blass JP. Decreased synthesis of actylcholine accompanying impaired oxidation of pyruvic acid in rat brain minces. Biochem J 1975; 148: 17-23.
57. Gibson GE, Peterson C. Aging decreases oxidative metabolism and the release and synthesis of acetylcholine. J Neurochem 1984; 37: 978-984.
58. Goate A, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irvin N, James L, Mant R, Newton P, Rooke K, Roques P, Talbot C, Perieak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Hardy J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706.
59. Goldgaber D, Lerman MJ, McBride OW, Saffiotti V, Gajdusek DC. Characterization and chromosomal localization of DNA encoding brain amyloid of Alzheimer's disease. Science 1987; 235: 877-880.
60. Goldstein GW. Blood-brain barrier in toxic encephalopathies. Neurobiol Aging 1994; 15: 237-238.
61. Gottfries CG. Neurochemical aspects of dementia disorders. Dementia 1990; 1: 56-64.
62. Goudsmit E, Hofman MA, Fliers E, Swaab DF. The supraoptic and paraventricular nuclei of the human hypothalamus in relation to sex, age and Alzheimer's disease. Neurobiol Aging 1990; 11: 529-536.
63. Graves AB, White E, Koepsell TD, Riefler BV, Belle G van, Larson EB, Raskind M. The association between head trauma and Alzheimer's disease. Am J Epidemiol 1990; 131: 491-501.
64. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989; 10: 593-602.
65. Gur RC, Mozley LH, Mozley PD, Resnick SM, Karp JS, Alavi A, Arnold SE, Gur RE. Sex differences in regional cerebral glucose metabolism during a resting state. Science 1995; 267: 528-531.
66. Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 1992; 357: 500-503.
67. Hardy J, Goate A, Owen M, Rossor N. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 1989; ii: 743.
68. Harman D. Free radical theory of aging: consequences of mitochondrial aging. Age 1983; 6: 86-94.
69. Harman D. Role of free radicals in aging and disease. Ann NY Acad Sci 1992; 673: 126-141.
70. Harman D. Free radical theory of aging: a hypothesis on pathogenesis of senile dementia of the Alzheimer's type. Age 1993; 16: 23-30.
71. Hattori K, Tanaka M, Sugiyama S, Obayashi T, Ito T, Satake T, Hanakir Y, Asai J, Nagano M, Ozawa T. Age dependent increase in deleted mitochondrial DNA in the human heart: possible contributory factor to presbycardia. Am Heart J 1991; 121: 1735-1742.
72. Haxby JV, Grady CL, Duara R, Schlageter N, Berg G, Rapoport SI. Neocortical metabolic abnormalities precede non-memory cognitive deficits in early Alzheimer-type dementia. Arch Neurol 1986; 43: 882-885.
73. Heiss WD, Hebold I, Klinkhammer P, Ziffling P, Szelies B, Pawlik G, Herholz K. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. J Cereb Blood Metab 1988; 8: 613-617.
74. Heiss WD, Kessler J, Slansky J, Mielke R, Szelies B, Herholz K. Activations PET as an instrument to determine therapeutic efficacy in Alzheimer's disease. Ann NY Acad Sci 1993; 695: 327-331.
75. Heiss WD, Szelies B, Kesseler J, Herholz K. Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann NY Acad Sci 1991; 640: 65-71.
76. Henneberry RC. The role of neuronal energy in the neurotoxicity of excitatory amino acids. Neurobiol Aging 1989; 10: 611-612.
77. Hertz MM, Paulson OB, Barry DI, Christiansen JS. Sevendsen PA. Insulin increases glucose transfer across the blood-brain barrier. J Clin Invest 1981; 67: 597-604.
78. Hoyer S. Glucose and related brain metabolism in normal aging. Age 1988; 11: 150-156.
79. Hoyer S. Brain glucose and energy metabolism during normal aging. Aging 1990; 2: 245-258.
80. Hoyer S. Abnormalities of glucose metabolism in Alzheimer's disease. Ann NY Acad Sci 1991; 640: 53-58.
81. Hoyer S. Brain energy metabolism and its significance for Alzheimer's disease. In: Iqbal K, Mchachlan DRC, Winblad B, Wisniewski HM, eds. Alzheimer's Disease: Basic Mechanisms, Diagnosis and Therapeutic Strategies. London: Wiley, 1991; 53-57.
82. Hoyer S. Abnormalities in brain glucose utilization and its impact on cellular and molecular mechanisms in sporadic dementia of Alzheimer type. Ann NY Acad Sci 1993; 695: 77-80.
83. Hoyer S. Age as risk factor for sporadic dementia of the Alzheimer type? Ann NY Acad Sci 1994; 719: 248-256.
84. Hoyer S, Nitsch R. Cerebral excess release of neurotransmitter amino acids subsequent to reduced cerebral glucose metabolism in early-onset dementia of Alzheimer type. J Neural Transm 1989; 75: 227-232.
85. Hoyer S, Nitsch R, Oesterreich K. Predominant abnormality in cerebral glucose utilization in late-onset dementia of the Alzheimer type: a cross-sectional comparison against advanced late-onset and incipient early-onset cases. J Neural Transm Park Dis Dement Sect 1991; 3: 1-14.
86. Ishiura S. Proteolytic cleavage of the Alzheimer's disease amyloid A 4 precursor protein. J Neurochem 1991; 56: 363-369.
87. Iwangoff P, Armbruster R, Enz A, Meier-Ruge W. Glycolytic enzymes from human autoptic brain cortex: normal and demented cases. Mech Ageing Dev 1980; 14: 203-209.
88. Iwangoff P, Armbruster R, Enz A, Meier-Ruge W, Sandoz P. Glycolytic enzymes from human autoptic brain cortex: normally aged and demented cases. In: Roberts PI, ed. Biochemistry of Dementia. Chichester: Wiley & Sons, 1980; 258-262.
89. Iwangoff P, Reichlmeier K, Enz A, Meier-Ruge W. Neurochemical findings in physiological aging of the brain. Interdiscipl Topics Geront 1979; 15: 13-33.
90. Jagust WJ, Eberling JL, Richardson BC, Reed BR, Baker MG, Nordahl TE, Budinger T. The cortical topography of temporal lobe hypometabolism in early Alzheimer's disease. Brain Res 1993; 629: 189-198.
91. Jagust W, Friedland R, Budinger T, Koss E, Ober B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology 1988; 38: 909-912.
92. Jendroska K, Cervos-Navarro J, Poewe W. Deposition of beta-amyloid associated with cerebral hypoxia. Clin Neuropathol 1993; 12: 252.
93. Kalaria RN, Bhatti SU, Lust WD, Perry G. The amyloid precursor protein in ischemic brain injury and chronic hypoperfusion. Ann NY Acad Sci 1993; 695: 190-193.
94. Kennedy AM, Frackowiak RSJ, Newman SK, Bloomfield PM, Seaward J, Roques P, Lewington G, Cunningham VJ, Rossor MN. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Let 1995; 186: 17-20.
95. Kessler J, Herholz K, Grond M, Heiss WD. Impaired metabolic activation in Alzheimer's disease: A PET study during continuous visual recognition. Neuropsychologia 1991; 29: 229-243.
96. Khachaturian ZS. Calcium regulation: final common pathway for age associated neurodegenerative processes. Neurosci Res Comm 1993; 13: 3-6.
97. Koh K, Ray R, Lee J, Nair A, Ho T, Ang C. Dementia in elderly patients: can the 3R mental stimulation programme improve mental status? Age and Ageing 1994; 23: 195-199.
98. Koo EH, Park L, Selkoe DJ. Amyloid β-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 1993; 90: 4748-4752.
99. Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A, Beyreuther K, Fischer P, Masters CL. Precursor of amyloid protein in Alzheimer's disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci USA 1990; 87: 1561-1565.
100. Kosik KS. Alzheimer plaques and tangles: advances on both fronts. TINS 1991; 14: 218-219.
101. Kosik KS. Alzheimer's disease: a cell biological perspective. Science 1992; 256: 780-783.
102. Kowall NW. Beta amyloid neurotoxicity and neuronal degeneration in Alzheimer's disease. Neurobiol Aging 1994; 15: 257-258.
103. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci USA 1991; 88: 7247-7251.
104. Kowall NW, McKee AC, Yankner BA, Beal MF. In vivo neurotoxicity of beta amyloid [β (1-40)] and the β (25-35) fragment. Neurobiol Aging 1992; 13: 537-542.
105. Landin K, Blennow K, Wallin A, Gottfries CG. Low blood pressure and blood glucose levels in Alzheimer's disease: evidence for a hypometabolic disorder? J Intern Med 1993; 233: 357-363.
106. Leibovitz BE, Siegel BV. Aspects of free radical reactions in biological systems. J Gerontol 1980; 35: 45-56.
107. Linnane AW, Baumer A, Maxwell RJ, Preston H, Zhang C, Marzuki S. Mitochondrial gene mutation: the ageing process and degenerative diseases. Biochem Int 1990; 22: 1067-1076.
108. Linnane AW, Marzuki S, Ozawa T, Tanaka M. Mitochondrial DNA mutations as an important contribution to aging and degenerative diseases. Lancet 1989; i: 642-645.
109. London ED, Walovitch RC. Cerebral glucose metabolism in aging rodents: effects of co-dergocrine. J Pharmacol 1985; 16 (suppl 3): 73-84.
110. Mann DMA. Pathological correlation of dementia in Alzheimer's disease. Neurobiol Aging 1994; 15: 357-360.
111. Manning CA, Hall JL, Gold PE. Glucose effects on memory and other neuropsychological tests in elderly humans. Psychol Sci 1990; 5: 307-311.
112. Manning CA, Parsons MW, Gold PE. Anterograde and retrograde enhancement of 24-hour memory by glucose in elderly humans. Behav Neural Biol 1992; 58: 125-130.
113. Manning CA, Ragozzino E, Gold PE. Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 1993; 14: 523-528.
114. Masters CL, Beyreuther K. Neuronal origin of a cerebral amyloidogenic proteins: Their role in Alzheimer's disease and unconventional virus disease of the nervous system. In: CIBA Foundation Sympos. 126, Selective Neuronal Death. Chichester: Wiley & Sons, 1987; 49-64.
115. 2+ homeostasis in Alzheimer's disease. TINS 1993; 16: 409-414.
116. McGeer PL, Kamo H, Harrop R, Li DK, Tuokko H, McGeer EG, Adam MJ, Ammann W, Beattie BL, Caline DB. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. Can Med Assoc J 1986; 134: 597-607.
117. Meguro K, Doi C, Ueda M, Yamaguchi T, Matsui H, Kinomura S, Itoh M, Yamada K, Sasaki H. Decreased cerebral glucose metabolism associated with mental deterioration in multi-infarct dementia. Neuroradiology 1991; 33: 305-309.
118. Meier-Ruge W. Neurochemistry of the aging brain and senile dementia. In: Gaitz CM, Samorajski T, eds. Aging 2000: Our Health Care Destiny. New York: Springer 1985; 101-112.
119. Meier-Ruge W. Effects of prolonged co-dergocrine mesylate (Hydergine®) treatment on local cerebral glucose uptake in aged Fischer 344 rats. Arch Gerontol Geriatr 1986; 5: 65-77.
120. Meier-Ruge W. Senile dementia - a disease of exhaustion of functional brain reserve capacity. Excerpt Med Curr Clin Pract Series 1990; 59: 371-375.
121. Meier-Ruge W, Bertoni-Freddari C, Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology 1994; 40: 246-252.
122. Meier-Ruge W, Hunziker O, Iwangoff P. Senile dementia: a threshold phenomenon of normal aging? A contribution of the functional reserve hypothesis of the brain. Ann NY Acad Sci 1991; 621: 104-118.
123. Meier-Ruge W, Iwangoff P, Bertoni-Freddari C. What is primary and what secondary for amyloid in Alzheimer's disease. Ann NY Acad Sci 1994; 719: 230-237.
124. Meier-Ruge W. Neurochemical enzyme changes in Alzheimer's and Pick's disease. Arch Gerontol Geriatr 1984; 3: 161-165.
125. Meier-Ruge W, Ulrich J, Abdel-Al S. Senile dementia: outlook for the future. In: Wertheimer J, Marris M, eds, Stereologic Findings in Normal Brain Aging and Alzheimer's Disease. New York: Alan R. Liss, 1984; 125-135.
126. Meier-Ruge W, Ulrich J, Stähelin. Morphometric investigation of nerve cells, neurophil and senile plaques in senile dementia of the Alzheimer type. Arch Gerontol Geriatr 1985; 4: 219-229.
127. Messier C, White NM. Memory improvement by glucose, fructose and two glucose analogs: a possible effect on peripheral glucose transport. Behav Neural Biol 1987; 48: 104-127.
128. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging 1992; 13: 93-98.
129. Milward EA, Papadopoulos R, Fuller SJ, Moir RD, Small D, Beyreuther K, Masters CL. The amyloid protein precursor of the Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 1992; 9: 129-137.
130. Miquel J. An integrated theory of aging as the result of mitochondrial-DNA mutation in differentiated cells. Arch Gerontol Geriatr 1991; 12: 99-117.
131. Miquel J, Fleming JE. A two-step hypothesis on the mechanisms of in vitro cell aging: cell differentiation followed by intrinsic mitochondrial mutagenesis. Exp Geront 1984; 19: 31-36.
132. Miquel J, Fleming J. Theoretical and experimental support for an "oxygen radical-mitochondrial injury" hypothesis. In: Johnson JE Jr, Walford R, Harman D, Miquel J, eds. Free Radicals, Aging and Degenerative Diseases. New York: Alan R. Liss, 1986; 51-74.
133. Mountjoy CQ, Rossor MN, Evans NJR, Reynolds GP, Evans H, Roth M, Iversen LL, Emson P. Biochemical and neuropathological changes in the brain and their correlation to the severity of dementia in Alzheimer's disease. In Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpsom GM, eds. Biological Psychiatry. New York: Elsevier, 1986; 1415-1417.
134. Mucke L, Masliah E, Johnson WB, Ruppe Md, Alford M, Rockenstein EM, Forss-Petter S, Pietropaolo M, Mallory M, Abraham CR. Synaptotrophic effects of human amyloid βprotein precursors on the cortex of transgenic mice. Brain Res 1994; 666: 151-167.
135. Murphy DG, Bottomley PA, Salerno JA, DeCarli C, Mentis MJ, Grady CL, Teichberg D, Giacometti KR, Rosenberg JM, Hardy CJ. An in vivo study of phosphorus and glucose metabolism in Alzheimer's disease using magnetic resonance spectroscopy and PET. Arch Gen Psychiatr 1993; 50: 341-349.
136. Mutisya EM, Bowling AC, Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 1994; 63: 2179-2184.
137. Nagasawa H, Kogure K, Kawaschima K, Ido T, Itoh M, Hatazawa J. Effects of co-dergocrine mesylate (Hydergine) in multi-infarct dementia as evaluated by positron emission tomography. Tohoku J Exp Med 1990; 162: 225-233.
138. Nagley P, Mackay JR, Baumer A, Maxwell RJ, Vaillant F, Wang Z, Zhang C, Linnane A. Mitochondrial DNA mutation associated with aging and degenerative disease. Ann NY Acad Sci 1992; 673: 92-102.
139. Newsholme EA, Start C. Regulation in Metabolism. Chichester: Wiley, 1973.
140. Nixon RA, Cataldo MA. Free radicals, proteolysis, and the degeneration of neurons in Alzheimer's disease: how essential is the beta-amyloid link? Neurobiol Aging 1994; 15: 463-469.
141. Nixon RA, Cataldo AM, Paskevich PA, Hamilton DJ, Wheelock TR, Kanaley-Andrews L. The lysosomal system in neurons. Involvement of multiple stages of Alzheimer's disease pathogenesis. Ann NY Acad Sci 1992; 674: 65-88.
142. Nohl H. Oxygen radical release in mitochondria: influence of age. In: Johnson JE Jr, Walford R, Harman D, Miquel J, eds. Free Radicals, Aging, and Degenerative Diseases. New York: Alan R. Liss, 1986; 77-97.
143. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 1988; 451: 205-212.
144. Pendlebury WW, Solomon PR. Alzheimer's disease: therapeutic strategies for the 1990s. Neurobiol Aging 1994; 15: 287-289.
145. Perry EK, Perry RH, Tomlinson BE, Blessed G, Gibson PH. Coenzyme A acetylating enzymes in Alzheimer's disease: possible cholinergic "compartment" of pyruvate dehydrogenase. Neurosci Lett 1980; 18: 105-110.
146. Perry RH, Candy JM, Perry EK. Extensive loss of choline acetyltransferase activity is not reflected by neuronal loss in the nucleus of Meynert in Alzheimer's disease. Neurosci Lett 1982; 33: 311-315.
147. Polinsky RJ, Noble H, DiChiro G, Nee LE, Feldman RG, Brown RT. Dominantly inherited Alzheimer's disease: cerebral glucose metabolism. J Neurol Neurosurg Psychiatr 1987; 50: 752.
148. Potter H. Review and hypothesis: Alzheimer's disease and Down syndrome chromosome 21 nondisjunction may underlie both disorders. Am J Hum Genet 1991; 48: 1192-1200.
149. Rapoport SI, Horwitz B, Grady CL, Haxby JV, DeCarli C, Schapiro MB. Abnormal brain glucose metabolism in Alzheimer's disease, as measured by positron emission tomography. Adv Exp Med Biol 1991; 291: 231-248.
150. Rausch R, Henry TR, Ary CM, Engel J Jr, Mazziotta J. Asymmetric interictal glucose hypometabolism and cognitive performance in epileptic patients. Arch Neurol 1994; 51: 139-144.
151. Regland B, Gottfries CG. The role of amyloid β-protein in Alzheimer's disease. Lancet 1992; 340: 467-469.
152. Rincny J, Tucek S. Relations between the content of acetylcoenzyme A and acetylcholine in brain slices. Biochem J 1980; 188: 683-688.
153. Roberts GW, Allsop D, Bruton CJ. The occult aftermath of boxing. J Neurol Neurosurg Psychiatr 1990; 53: 373-378.
154. Roch JM, Jin LW, Ninomiya H, Schubert D, Saitoh T. Biologically active domain of the secreted form of the amyloid β/ A4 protein precursor. Ann NY Acad Sci 1993; 695: 149-157.
155. Roder HM, Eden PA, Ingram VM. Brain protein kinase PK 40 converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Comm 1993; 193: 639-647.
156. Roder HM, Ingram VM. Two novel kinases phosphorylate tau and the KSP site of heavy neurofilaments subunits in high stoichiometric ratios. J Neurosci 1991; 11: 3325-3343.
157. Roses AD. Apolipoprotein E-4 and apolipoprotein E-2 are susceptibility genes that affect the rate of disease expressivity of late-onset familial and sporadic Alzheimer's disease. In: Dall JLC, Ermini M, Herrling PL, Meier-Ruge W, Stähelin HB, Staufenbiel M, eds. Adaptations in Aging. London, San Diego, New York: Academic Press, 1995; 171-186.
158. Roth M. Some strategies for tackling the problems of senile dementia and related disorders within the next decade. Danish Med Bull 1985; 35 (suppl 1): 92-111.
159. Saitoh T, Brugge K. Is amyloid causally involved in pathophysiology of Alzheimer's disease? Neurobiol Aging 1994; 15: 461-462.
160. Saitoh T, Jimoto DS. Altered protein kinase and amyloid β-protein precursor in Alzheimer's disease: which conies first? In: Boiler F, Rascol A, Christen Y, Kazman R, Signoret JL, eds. Biological Markers of Alzheimer's Disease. Berlin, Heidelberg, New York: Springer, 1989; 103-117.
161. Sambamurti K, Shioi J, Anderson JP, Pappolla MA, Robakis NK. Evidence for intracellular cleavage of the Alzheimer's amyloid precursor in PC12 cells. J Neurosci Res 1992; 33: 319-329.
162. Selkoe DJ, Bell DS, Podlinsny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987; 235: 873-877.
163. Selkoe DJ, Polisny MD, Joachim C, Vickers EA, Lee G, Fritz LC, Oltersdorf T. Beta-amyloid precursor protein of Alzheimer's disease occurs at 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci USA 1988; 85: 7341-7345.
164. Shea TB, Clarke JF, Wheelock TR, Paskevich PA, Nixon RA. Aluminium salts induce the accumulation of neurofilaments in perikarya of NB2a/d1 neuroblastoma. Brain Res 1989; 492: 53-64.
165. Sheu KF, Kim YT, Blass JP, Wekster HE. An immunochemical study of pyruvate dehydrogenase deficit in Alzheimer brains. Ann Neurol 1985; 17: 444-449.
166. Siesjö BK. Brain Energy Metabolism. Chichester: Wiley, 1978; 1-55.
167. Siesjö BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression; a unifying hypothesis. J Cereb Blood Flow Metab 1989; 8: 127-140.
168. Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, Davison AN. Presynaptic cholinergic dysfunction in patients with dementia. Neurochem 1983; 40: 503-509.
169. 14C) glucose by tissue prisms from human neocortex. Biochem J 1984; 196: 867-876.
170. 14C) glucose in vitro in human neocortex. J Neurochem 1983; 41: 1329-1334.
171. Sims NR, Finegan JP, Blass JP, Brown DM, Neary D. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 1987; 436: 30-38.
172. Sinex ME, Merril CR. Alzheimer's disease, Down syndrome and aging. Ann NY Acad Sci 1982; Vol 396.
173. Sinha S, Lieberburg I. Normal metabolism of the amyloid precursor protein (APP). Neurodegeneration 1992; 1: 169-175.
174. Sisodia SS. β-Amyloid precursor protein cleavage by a membrane-bound protease. Proc Natl Acad Sci USA 1992; 89: 6075-6079.
175. Small DH, Nurcombe V, Reed G, Clarris H, Moir R, Beyreuther K, Masters CL. A heparin-binding domain in the amyloid protein precursor of Alzheimer's disease is involved in the regulation of neuritic outgrowth. J Neurosci 1994; 14: 2117-2127.
176. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps MF, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, Guze BH, Corder EH, Saunders AM, Haines JL, Pericak-Vance MA, Roses AD. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 1995; 273: 942-947.
177. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, Colomb J, Ferris SH, Reisberg B, Ciaravino J. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992; 49: 1142-1150.
178. Summers WK, Majovski V, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-1245.
179. Swaab DF. Brain aging and Alzheimer's disease, "wear and tear" versus "use it or lose it". Neurobiol Aging 1991; 12: 317-324.
180. Swaab DF, Hofman MA, Lucassen PJ, Salehi A, Uylings BM. Neuronal atrophy, not cell death, is the main hallmark of Alzheimer's disease. Neurobiol Aging 1994; 15: 369-371.
181. Schapiro MB, Grady CL, Kumar A, Herscovitch P, Haxby JV, Moore A, White B, Friedland RP, Rapoport SI. Regional cerebral glucose metabolism is normal in young adults with Down syndrome. J Cereb Blood Flow Metab 1990; 10: 199-206.
182. Stephenson DT, Rash K, Clemens JA. Amyloid precursor protein accumulates in regions of neurodegeneration following focal cerebral ischemia in the rat. Brain Res 1992; 593: 128-135.
183. Stern Y, Alexander GE, Prohovnik I, Stricks L, Link B, Lennon MC, Mayeux R. Relationship between lifetime occupation and parietal flow, implications for a reserve against Alzheimer's disease pathology. Neurology 1995; 45: 55-60.
184. Strittmatter WJ, Saunders AM, Schmechel DE, Pericak-Vance MA, Enghild J, Salvesen GS, Roses AD. Apolipoprotein E: high affinity binding to βA amyloid and increased frequency of type 4 allele in familial Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 1977-1981.
185. Tanzi RE, George-Hyslop PH St, Gusella JF. Molecular genetic approaches to Alzheimer's disease. TINS 1989; 12: 152-158.
186. Tanzi RE, Gusella JF, Watkins PC, Bruns GAP, George-Hyslop PH St, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL. Amyloid β protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987; 235: 880-884.
187. Tokuda T, Ikeda S, Yanagisawa N, Ihara Y, Glenner GG. Re-examination of ex-boxers' brains using immunohistochemistry with antibodies to amyloid β-protein and tau protein. Acta Neuropathol 1991; 82: 280-285.
188. Tomlinson BE, Blessed G, Roth M. Observation on the brains of demented old people. J Neurol Sci 1970; 11: 205-242.
189. Tsuji K, Nakamura Y, Ogata T, Shibata T, Kataoka K. Rapid decrease in ATP content without recovery phase during glutamate-induced cell death in cultured spinal neurons. Brain Res 1994; 662: 289-292.
190. Tsuzuki K, Fukatsu R, Takamaru Y, Fujii N, Takahata N. Potentially amyloidogenic fragment of 50 kDa and intracellular processing of amyloid precursor protein in cells cultured under leupeptin. Brain Res 1994; 659: 213-220.
191. Tucek S. Regulation of acetylcholine synthesis in the brain. J Neurochem 1985; 44: 11-21.
192. Tucek S, Ricny J, Dolezal V. Advances in the biology of cholinergic neurons. Adv Neurobiol 1990; 51: 109-115.
193. Walker E, Blumer D. The fate of world war II veterans with post-traumatic seizures. Arch Neurol 1989; 46: 23-26.
194. Wallace DC. Mitochondrial genetics: a paradigm for . aging and degenerative diseases? Science 1992; 256: 628-632.
195. Walovitch RC, Ingram DK, Spangler EL, London ED. Co-dergocrine, cerebral glucose utilization and maze performance in middle-aged rats. Pharmacol Biochem Behav 1987; 26: 95-101.
196. Watt JA, Pike CJ, Walencewicz-Wassermann AJ, Cotman CW. Ultrastructural analysis of β-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res 1994; 661: 147-156.
197. Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981; 10: 122-126.
198. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, DeLong MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1983; 215: 1237-1239.
199. Whitson JS, Glabe CG, Shintani E, Aber A, Cotman CW. Beta-amyloid protein promotes neuritic branching in hippocampal cultures. Neurosci Lett 1990; 110: 319-324.
200. Wickner WT. How ATP drives proteins across membranes. Science 1994; 266: 1197-1198.
201. Winkler J, Connor DJ, Frautschy SA, Behl C, Waite JJ, Cole GM, Thai LJ. Lack of long-term effects after β-amyloid protein injections in rat brain. Neurobiol Aging 1994; 15: 601-607.
202. Wisniewski HM, Terry RD. Morphology of the aging brain, human and animal. In: Ford DH, ed. Neuro-Biological Aspects of Maturation and Aging. Prog Brain Res 1973; 40: 1108-1109.
203. Yankner BA, Duffy LK, Kirschner DA. Neurotropic and neurotoxic effects of amyloid beta proteins: reversal by tachykinin neuropeptides. Science 1990; 250: 279-282.
204. Yesavage JA, Westphal J, Rush L. Senile dementia: combined pharmacologic and psychologic treatment. J Am Geriatr Soc 1981; 29: 164-171.
205. Zhang H, Sternberger NH, Rubinstein LJ, Herman MM, Binder LI, Sternberger LA. Abnormal processing of multiple proteins in Alzheimer disease. Proc Natl Acad Sci USA 1989; 86: 8045-8049.
206. Roch JM, Masliah E, Roche-Levecq AC, Sundsmo MP, Otero DA, Veinbergs I, Saitoh T. Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid β/A4 protein precursor. Proc Natl Acad Sci USA 1994; 91: 7650-7654.
207. Jendroska K, Poewe W, Daniel SE, Pluess J, Iwerssen-Schmidt H, Paulsen J, Barthel S, Schelosky L, Cervós-Navarro J, DeArmond SJ. Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain. Acta Neuropathol 1995; 90: 461-466.